DSTL - ETF AI Analysis

Top Page

Distillate US Fundamental Stability & Value ETF (DSTL)

Rating:72Outperform

Price Target:―

DSTL, the Distillate US Fundamental Stability & Value ETF, earns a solid overall rating thanks to several high-quality, stable companies with strong financial performance and strategic growth plans. Leading holdings like Merck, Johnson & Johnson, Bristol-Myers Squibb, Cisco, and Amgen support the fund’s quality by combining robust earnings, attractive or fair valuations, and positive outlooks from their pipelines and initiatives. The main risk factor is that several key holdings face issues such as high debt, valuation concerns, and segment-specific challenges, which could weigh on future returns if not well managed.

Positive Factors

Balanced Sector Mix

Holdings are spread across technology, health care, industrials, and consumer sectors, which helps reduce reliance on any single part of the market.

Moderate Concentration in Top Holdings

The top positions each make up only a small slice of the fund, limiting the impact if any one company runs into trouble.

Steady Recent Performance

The ETF has shown generally positive performance over the past month, three months, and year to date, indicating steady momentum.

Negative Factors

High U.S. Concentration

Almost all assets are invested in U.S. companies, offering little geographic diversification outside the United States.

Mixed Performance Among Top Holdings

Several of the largest positions, such as AbbVie, T-Mobile US, Cisco, and Comcast, have shown weak year-to-date performance, which can drag on overall returns.

Above-Rock-Bottom Expense Ratio

While not extremely high, the fund’s expense ratio is higher than the very cheapest index ETFs, slightly reducing net returns over time.

DSTL vs. SPDR S&P 500 ETF (SPY)

AUM1.88B

RegionNorth America

Expense Ratio0.39%

Beta0.72

IssuerDistillate

Inception DateOct 24, 2018

Dividend Yield1.32%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume110,125

30 Day Avg. Volume109,376

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

69.52

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering101

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

DSTL Summary

DSTL is an exchange-traded fund that invests in large U.S. companies chosen for financial stability and good value, rather than tracking a specific index. It focuses on strong, established businesses across sectors like technology, health care, and consumer goods. Well-known holdings include Johnson & Johnson and Procter & Gamble. Someone might invest in DSTL to get diversified exposure to high-quality U.S. stocks with an emphasis on steady cash flows and reasonable prices. A key risk is that the fund still holds stocks, so its value can go up and down with the overall stock market.

How much will it cost me?The expense ratio for the Distillate US Fundamental Stability & Value ETF (DSTL) is 0.39%, which means you’ll pay $3.90 per year for every $1,000 you invest. This is slightly higher than the average for passively managed ETFs because DSTL uses a strategic, rules-based approach to select financially stable and value-oriented large-cap U.S. companies.

What would affect this ETF?DSTL's focus on financially stable U.S. large-cap companies, particularly in sectors like healthcare and technology, positions it to benefit from advancements in medical innovation and tech growth. However, rising interest rates or economic slowdowns could negatively impact consumer spending and corporate earnings, affecting sectors like consumer cyclical and industrials. Regulatory changes in healthcare or technology could also influence the ETF's performance.

DSTL Top 10 Holdings

DSTL is leaning heavily on steady, defensive giants, with health care names like Merck, Johnson & Johnson, Amgen, and Bristol-Myers providing much of the recent lift as their shares have been rising and their pipelines keep investors optimistic. Lockheed Martin has also been a standout, powering ahead on strong defense demand. On the softer side, AbbVie has been more mixed, occasionally losing steam despite its long-term story. Overall, this is a U.S.-only fund tilted toward stable, cash-generating health care and communication names rather than flashy high-growth tech.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
MRK	Merck & Company	2.65%	$49.35M	$287.32B	24.49%	80 Outperform
ABBV	AbbVie	2.54%	$47.30M	$402.58B	7.36%	66 Neutral
TMUS	T Mobile US	2.52%	$47.00M	$235.18B	-16.50%	76 Outperform
JNJ	Johnson & Johnson	2.30%	$42.85M	$585.58B	49.21%	78 Outperform
PG	Procter & Gamble	2.12%	$39.51M	$356.32B	-8.94%	69 Neutral
BMY	Bristol-Myers Squibb	2.01%	$37.50M	$122.15B	0.28%	78 Outperform
CMCSA	Comcast	1.88%	$35.01M	$109.99B	-13.13%	74 Outperform
CSCO	Cisco Systems	1.87%	$34.89M	$308.49B	29.18%	77 Outperform
AMGN	Amgen	1.68%	$31.22M	$203.57B	20.84%	77 Outperform
LMT	Lockheed Martin	1.64%	$30.50M	$149.43B	40.73%	70 Outperform

DSTL Technical Analysis

Technical Analysis Sentiment

Negative

Last Price―

Price Trends

50DMA

60.55

Negative

100DMA

59.21

Positive

200DMA

57.50

Positive

Market Momentum

MACD

-0.13

Positive

RSI

35.61

Neutral

STOCH

23.31

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DSTL, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 61.22, equal to the 50-day MA of 60.55, and equal to the 200-day MA of 57.50, indicating a neutral trend. The MACD of -0.13 indicates Positive momentum. The RSI at 35.61 is Neutral, neither overbought nor oversold. The STOCH value of 23.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DSTL.

DSTL Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
DSTL	―	―	$1.88B	0.39%	72 Outperform
PVAL	―	―	$8.61B	0.55%	72 Outperform
JAVA	―	―	$5.86B	0.44%	71 Outperform
DFLV	―	―	$5.30B	0.21%	73 Outperform
FELV	―	―	$2.78B	0.18%	72 Outperform
SEIV	―	―	$1.15B	0.15%	72 Outperform

Performance Comparison

DSTL

Distillate US Fundamental Stability & Value ETF

58.66

5.22

9.77%

PVAL

Putnam Focused Large Cap Value ETF

―

JAVA

JPMorgan Active Value ETF

―

DFLV

Dimensional US Large Cap Value ETF

―

FELV

Fidelity Enhanced Large Cap Value ETF

―

SEIV

SEI Enhanced U.S. Large Cap Value Factor ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents